Noah Agada

605 total citations
20 papers, 431 citations indexed

About

Noah Agada is a scholar working on Immunology, Epidemiology and Genetics. According to data from OpenAlex, Noah Agada has authored 20 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 6 papers in Epidemiology and 5 papers in Genetics. Recurrent topics in Noah Agada's work include Psoriasis: Treatment and Pathogenesis (10 papers), Inflammatory Bowel Disease (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Noah Agada is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (10 papers), Inflammatory Bowel Disease (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Noah Agada collaborates with scholars based in United States, Canada and Germany. Noah Agada's co-authors include Kristian Reich, Melinda Gooderham, Andrew Blauvelt, Susan Ball, Lars Iversen, Lu Zhang, Richard G. Langley, Wen Xu, Kim Papp and Beth A. Pangallo and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Frontiers in Immunology and The American Journal of Gastroenterology.

In The Last Decade

Noah Agada

20 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noah Agada United States	10	297	161	80	49	49	20	431
William N. Malatestinic United States	12	376 1.3×	192 1.2×	167 2.1×	45 0.9×	61 1.2×	53	516
Tobias Weberschock Germany	13	137 0.5×	190 1.2×	55 0.7×	116 2.4×	48 1.0×	22	461
Ralph von Kiedrowski Germany	16	547 1.8×	475 3.0×	113 1.4×	77 1.6×	102 2.1×	60	750
Klaus Strömer Germany	13	233 0.8×	290 1.8×	63 0.8×	48 1.0×	48 1.0×	35	473
Cynthia Madden United States	12	602 2.0×	379 2.4×	153 1.9×	151 3.1×	107 2.2×	20	862
Jacob Groenendyk United States	7	149 0.5×	42 0.3×	63 0.8×	27 0.6×	31 0.6×	14	294
Marco Mariani Italy	12	124 0.4×	71 0.4×	27 0.3×	36 0.7×	39 0.8×	30	388
J. Vanderpuye-Orgle United States	8	121 0.4×	57 0.4×	16 0.2×	32 0.7×	49 1.0×	19	371
Delano Pathirana Germany	9	142 0.5×	160 1.0×	15 0.2×	14 0.3×	28 0.6×	12	409
Natan R. Kahan Israel	15	41 0.1×	34 0.2×	114 1.4×	50 1.0×	24 0.5×	31	396

Countries citing papers authored by Noah Agada

Since Specialization

Citations

This map shows the geographic impact of Noah Agada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noah Agada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noah Agada more than expected).

Fields of papers citing papers by Noah Agada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noah Agada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noah Agada. The network helps show where Noah Agada may publish in the future.

Co-authorship network of co-authors of Noah Agada

This figure shows the co-authorship network connecting the top 25 collaborators of Noah Agada. A scholar is included among the top collaborators of Noah Agada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noah Agada. Noah Agada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dubinsky, Marla C., Vipul Jairath, Brian G. Feagan, et al.. (2023). Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterology. 10(1). e001115–e001115. 8 indexed citations

Pai, Rish K., Gert De Hertogh, Walter Reinisch, et al.. (2023). Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease. Zeitschrift für Gastroenterologie. 61(5). e183–e184. 1 indexed citations

Agada, Noah, Matthew S. Kelly, Jonathan S. Tam, et al.. (2023). Case Report: Nontuberculous mycobacterial infections in children with complete DiGeorge anomaly. Frontiers in Immunology. 14. 1078976–1078976. 4 indexed citations

Pai, Rish K., Gert De Hertogh, Walter Reinisch, et al.. (2021). P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease. Journal of Crohn s and Colitis. 15(Supplement_1). S404–S406. 4 indexed citations

Combe, Bernard, Proton Rahman, Hideto Kameda, et al.. (2020). Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research & Therapy. 22(1). 14–14. 34 indexed citations

Sandborn, William J., Bruce E. Sands, Monika Fischer, et al.. (2020). S0705 Evaluation of Symptom Improvement During Induction in Patients With Crohn's Disease Treated With Mirikizumab. The American Journal of Gastroenterology. 115(1). S354–S354. 4 indexed citations

Mrowietz, Ulrich, Elisabeth Riedl, Stefan Winkler, et al.. (2020). No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. Journal of the American Academy of Dermatology. 83(5). 1436–1439. 12 indexed citations

Goldblum, Orin M., L. Renda, Noah Agada, et al.. (2019). Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis. Dermatology and Therapy. 10(1). 99–106. 23 indexed citations

Armstrong, April W., C. Paul, L. Puig, et al.. (2019). Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatology and Therapy. 10(1). 133–150. 54 indexed citations

10.

Langley, Richard G., Kim Papp, Melinda Gooderham, et al.. (2018). Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). British Journal of Dermatology. 178(6). 1315–1323. 48 indexed citations

11.

Langley, Richard G., Alexa B. Kimball, Beth A. Pangallo, et al.. (2018). Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials. Journal of the European Academy of Dermatology and Venereology. 33(2). 333–339. 46 indexed citations

12.

Shear, Neil H., C. Paul, Andrew Blauvelt, et al.. (2018). Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.. PubMed. 17(2). 200–206. 19 indexed citations

13.

Reich, Kristian, Craig L. Leonardi, Kim Papp, et al.. (2017). Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis”. Journal of Investigative Dermatology. 137(12). 2642–2644. 2 indexed citations

14.

Blauvelt, Andrew, Melinda Gooderham, Lars Iversen, et al.. (2017). 398 Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3). Journal of Investigative Dermatology. 137(10). S260–S260. 5 indexed citations

15.

Blauvelt, Andrew, Melinda Gooderham, Lars Iversen, et al.. (2017). Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). Journal of the American Academy of Dermatology. 77(5). 855–862. 93 indexed citations

16.

Agada, Noah, et al.. (2015). Disseminated Atypical Mycobacterial Infection in Three Patients with Complete Digeorge Anomaly. Journal of Allergy and Clinical Immunology. 135(2). AB10–AB10. 2 indexed citations

17.

McCarthy, Melissa L., Ru Ding, Scott L. Zeger, et al.. (2011). A Randomized Controlled Trial of the Effect of Service Delivery Information on Patient Satisfaction in an Emergency Department Fast Track. Academic Emergency Medicine. 18(7). 674–685. 36 indexed citations

18.

Bessman, Sara C., et al.. (2011). Comparing National Institutes of Health Funding of Emergency Medicine to Four Medical Specialties. Academic Emergency Medicine. 18(9). 1001–1004. 18 indexed citations

19.

Agada, Noah, et al.. (2007). Microalbuminuria and clinical correlates in black African patients with type 2 diabetes.. PubMed. 25(4). 279–83. 9 indexed citations

20.

Agada, Noah, et al.. (2006). Diabetes care in Nigeria: time for a paradigm shift.. PubMed. 35(2). 155–9. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact